Sanofi and GSK Initiate P-II Study of their Adjuvanted Recombinant Protein-Based COVID-19 Vaccine

Shots:

  • The companies reported the initiation of a P-II dose-finding study assessing the safety, reactogenicity, and immunogenicity of two injections given 21 days apart in 720 adults aged ≥18yrs.
  • The P-II study assesses the potential for refined antigen formulation to achieve an optimal immune response, including in older adults. If P-II results are positive, the P-III study is expected to be initiated in Q2’21 with vaccine anticipated to be available in Q4’21
  • In parallel to the P-II study, Sanofi has commenced development work against new variants, which will be used to inform the next stages of the Sanofi/GSK development program

Click here ­to­ read full press release/ article | Ref: Sanofi | Image: BioSpace

The post Sanofi and GSK Initiate P-II Study of their Adjuvanted Recombinant Protein-Based COVID-19 Vaccine first appeared on PharmaShots.

Clover and Dynavax Plan to Initiate P-II/III Trial for Adjuvanted COVID-19 Vaccine Candidate

Shots:

  • Clover plans to initiate a global P-II/III efficacy trial with the S-Trimer COVID-19 vaccine candidate adjuvanted with CpG 1018 plus alum in the H1’2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021
  • Additionally, Clover discontinued their partnership with GSK to evaluate the S-Trimer vaccine candidate with GSK’s pandemic adjuvant system
  • The CEPI will continues to support Clover’s COVID-19 vaccine candidate and will fund its development through licensure

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Siakap Keli

The post Clover and Dynavax Plan to Initiate P-II/III Trial for Adjuvanted COVID-19 Vaccine Candidate first appeared on PharmaShots.